Telisotuzumab-vedotin

Drug Profile

Telisotuzumab-vedotin

Alternative Names: ABBV-399; ABT 399

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AbbVie
  • Developer AbbVie; Bristol-Myers Squibb
  • Class Antineoplastics; Auristatins; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Mitosis inhibitors; Proto oncogene protein c met inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 18 Oct 2017 AbbVie plans a phase I trial for Solid tumours (Late-stage disease) in Japan (IV) in November 2017 (NCT03311477)
  • 22 Sep 2017 Phase-I clinical trials in Non-small cell lung cancer (Second-line therapy or greater, Combination therapy, Late-stage disease) (IV)
  • 02 Jun 2017 Adverse events, efficacy data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top